Tufts CSDD: Adoption of AI is High Across Industry


Applied Clinical Trials

The pharmaceutical industry is adopting artificial intelligence (AI) on numerous fronts, from discovery and clinical development to risk assessment and safety monitoring, regulatory, and manufacturing, according to an analysis recently completed by the Tufts Center for the Study of Drug Development.

"Pharmaceutical and biotechnology companies as well as service providers now rely on AI technologies across all therapeutic areas, including most strongly for oncology, central nervous system, cardiovascular, immunology, rare diseases, and metabolic/endocrine diseases," said Mary Jo Lamberti, research assistant professor and associate director of sponsored research at Tufts CSDD, who led the analysis.

Parkih noted that the advent of precision medicine and targeted therapies, as well as increasing demand for new treatments for rare diseases, will drive further, likely exponential, growth, she said, especially as health authorities and industry develop standard policies and a regulatory framework to address concerns such as ethical use, bias, and validation.

Despite the widespread and growing embrace of AI in drug development, lack of adequate staff skills, difficulty in adapting unstructured data, and insufficient budgets remain major challenges to adopting AI, according to Tufts CSDD.

The analysis, summarized in the May/June Tufts CSDD Impact Report, released today, found that:

  • The clinical operations function makes the highest use of AI (61%), followed by pharmacovigilance/safety/risk management (57%), and information technology (IT) (55%).

  • 42% of respondents in a global survey reported that AI implementation is not centrally managed at their companies, while 20% indicated that it is managed by R&D and 12% said that it is overseen by the chief information officer.

  • 59% of respondents plan to expand AI staff through 2020, with the largest staffing increases slated for data scientists, computer scientists, IT specialists, and AI architects.

The survey generated responses from 402 industry professionals working for pharmaceutical or biotechnology companies, contract research organizations, technology/data providers, and other organizations in North America (61%), Europe (23%), Asia Pacific (11%), Latin America (2%), and Rest of World (3%).

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Related Content
© 2024 MJH Life Sciences

All rights reserved.